HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellness Market News: VSI, Mannatech Q3 Results, GoGenics, Hundred, Orgain Investments, One CBD Launch

Executive Summary

One CBD launches as opioid alternative; EMEA drives Mannatech sales; VSI slumps in final quarter before sale; $3.2m financing for GoGenics; $8m technology investment in hundredInc.; and Butterfly buys Orgain majority stake.

You may also be interested in...



Nestle Harvests Plant-Based Protein Firm Orgain As Latest US Nutrition Business Investment

Nestle Health Science has expanded its nutritional footprint steadily since 2017 but investing in Orgain, with option to fully acquire in 2024 brings its first business working exclusively with plant-based ingredients.

Vitamin Shoppe Launches Vthrive 'Clean' Brand, Opens Shops At LA Fitness Gyms

One month into being owned by investment firm, VSI launches Vthrive The Vitamin Shoppe brand of “simply clean” vitamins, minerals, supplements, and essential oils and is opening stores inside locations of national gym chain LA Fitness.

HBW Market News: VSI Focuses On First Offer, Nestle Invests In Consumer Health, Eosera Adds Products, Space, Staff

Vitamin Shoppe discloses preliminary plan for shareholder vote on $208m takeover offer; Nestle Health Science invests in SpoonfulOne early childhood food allergy prevention brand; and ear care product firm Eosera moves to facility twice as large and adds two products, four staff members.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel